Patents by Inventor Linda A. Morrow

Linda A. Morrow has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for modifying, diagnosing and screening for IGF-I sensitive cell barriers
    Patent number: 5736400
    Abstract: A method of chronic modification of cell barrier properties by exposing a cell to a modification-effective amount of IGF-I for at least about 7 days wherein the modification effective amount is between about 50 .mu.g/kg and less than about 500 .mu.g/kg is disclosed. Further disclosed is a method of chronic amelioration or reversal of insulin resistance as well as a method of diagnosing and screening for rhIGF-I sensitive cell barrier properties.
    Type: Grant
    Filed: December 2, 1996
    Date of Patent: April 7, 1998
    Inventors: Alan C. Moses, Linda A. Morrow, Jeffrey S. Flier
  • Method for modifying, diagnosing, and screening for IGF-I sensitive cell barrier properties
    Patent number: 5686408
    Abstract: A method of chronic modification of cell barrier properties by exposing a cell to a modification-effective amount of IGF-I for at least about 7 days wherein the modification effective amount is between about 50 .mu.g/kg and less than about 500 .mu.g/kg is disclosed. Further disclosed is a method of chronic amelioration or reversal of insulin resistance as well as a method of diagnosing and screening for rhIGF-I sensitive cell barrier properties.
    Type: Grant
    Filed: July 25, 1994
    Date of Patent: November 11, 1997
    Assignee: The Beth Israel Hospital Association
    Inventors: Alan C. Moses, Linda A. Morrow, Jeffrey S. Flier
  • Method for modifying, diagnosing, and screening for IGF-I sensitive cell barrier properties
    Patent number: 5637567
    Abstract: A method of chronic modification of cell barrier properties by exposing a cell to a modification-effective amount of IGF-I for at least about 7 days wherein the modification effective amount is between about 50 .mu.g/kg and less than about 500 .mu.g/kg is disclosed. Further disclosed is a method of chronic amelioration or reversal of insulin resistance as well as a method of diagnosing and screening for rhIGF-I sensitive cell barrier properties.
    Type: Grant
    Filed: May 8, 1995
    Date of Patent: June 10, 1997
    Assignee: The Beth Israel Hospital Association
    Inventors: Alan C. Moses, Linda A. Morrow, Jeffrey S. Flier
  • Method for treating insulin resistance with IGF-I
    Patent number: 5612312
    Abstract: A method of chronic modification of cell barrier properties by exposing a cell to a modification-effective amount of IGF-I for at least about 7 days wherein the modification effective amount is between about 50 .mu.g/kg and less than about 500 .mu.g/kg is disclosed. Further disclosed is a method of chronic amelioration or reversal of insulin resistance as well as a method of diagnosing and screening for rhIGF-I sensitive cell barrier properties.
    Type: Grant
    Filed: May 8, 1995
    Date of Patent: March 18, 1997
    Inventors: Alan C. Moses, Linda A. Morrow, Jeffrey S. Flier